39 completed. 39 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 39 | Completed 39 |
| Phase 2 | 3 | Completed 3 |
Follow Infectious Encephalitis: new trials by email Literature Review of Infectious Encephalitis trials Research Report on Infectious Encephalitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Immunogenicity, Safety, and Tolerability of a Tick-Borne Encephalitis (TBE) Vaccine in Healthy Japanese Participants 1 Year of Age and Older TBE vaccine 0.5 mL, TBE vaccine 0.25 mL - Tick-Borne Encephalitis | Phase 3 | Completed | Pfizer | 165 | 2021-01-18 | 2023-11-22 |
| Evaluate Safety and Immunogenicity of a Vero Cell-Derived JE Vaccine in 9-24 Months of Age Children in Vietnam JEVAX, JECEVAX - Japanese Encephalitis | Phase 3 | Completed | National Institute of Hygiene and Epidemiology, Vietnam | 655 | 2017-09-30 | 2018-09-17 |
| Study of a Single Primary Dose Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV®) in Healthy Subjects Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®) - Japanese Encephalitis | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 250 | 2015-06-01 | 2022-03-28 |
| New Study - Humoral Response to Tick-borne Encephalitis Vaccine in Elderly FSME-immune - Tick-borne Encephalitis | Phase 2 / Phase 3 | Completed | Sormland County Council, Sweden | 250 | 2015-01-01 | 2021-02-10 |
| A Clinical Trial for Inactivated Japanese Encephalitis Vaccine in Healthy Chinese Infants 0.5ml experimental vaccine on day 0,7 Vero cell-derived inactivated Japanese Encephalitis vaccine, 0.5ml experimental vaccine on day 0,28 Vero cell-derived inactivated Japanese Encephalitis vaccine, 0.5ml active comparator vaccine on day 0,7 inactivated freeze-dried Japanese Encephalitis vaccine(Vero cell) - Encephalitis | Phase 3 | Completed | Jiangsu Province Centers for Disease Control and Prevention | 900 | 2014-10-01 | 2016-09-01 |
| Study of a Booster Dose of IMOJEV® One Year After Primary Immunization in Healthy Children in South Korea IMOJEV - Japanese Encephalitis | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 119 | 2013-07-11 | 2022-03-28 |
| Safety and Immunogenicity of 2 Different Vaccination Schedules of Rabies and Japanese Encephalitis Vaccines in Healthy Adult Subjects Rabies, Japanese Encephalitis, Placebo - Rabies, Japanese Encephalitis | Phase 3 | Completed | Novartis Vaccines | 661 | 2012-08-01 | 2014-12-08 |
| A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults Typhoid Vi Polysaccharide Vaccine, Yellow Fever Vaccine, Japanese Encephalitis Vaccine - Meningococcal Disease, Meningococcal Meningitis | Phase 3 | Completed | Novartis | 552 | 2011-11-01 | 2014-03-11 |
| Humoral Response to Tick-borne Encephalitis Vaccine in Elderly FSME-immune - Tick-borne Encephalitis | Phase 2 / Phase 3 | Completed | Sormland County Council, Sweden | 200 | 2011-09-01 | 2015-11-18 |
| Study of a Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV™) Compared to CD.JEVAX™ in Toddlers Live attenuated Japanese encephalitis chimeric virus vaccine, Japanese encephalitis live attenuated vaccine (SA14 14 2 vaccine) - Japanese Encephalitis, Japanese Encephalitis Virus Disease | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 274 | 2011-07-01 | 2014-04-25 |
| Open-label, Randomized Study in a Pediatric Population in a JEV (Japanese Encephalitis Virus)-Endemic Country IXIARO - Japanese Encephalitis | Phase 3 | Completed | Valneva Austria GmbH | 300 | 2010-12-01 | 2014-12-19 |
| Long Term Immunity and Safety Following Vaccination With the JEV IC51 (IXIARO®, JESPECT®) in Pediatric Population In Non Endemic Countries. Uncontrolled, Ph3 FU-Study Blood draw, IC51 has given in the parent study IC51-322 - Japanese Encephalitis | Phase 3 | Completed | Valneva Austria GmbH | 23 | 2010-10-01 | 2020-03-18 |
| Study of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children Previously Immunized With JE-CV JE-CV Vaccine, Varicella Vaccine - Japanese Encephalitis, Varicella | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 454 | 2010-08-25 | 2022-03-28 |
| Study of Japanese Encephalitis Chimeric Virus Vaccine Given With Measles-Mumps-Rubella Vaccine in Taiwanese Toddlers Japanese encephalitis chimeric virus: Measles, mumps, and rubella live attenuated virus - Japanese Encephalitis, Measles | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 542 | 2010-08-01 | 2014-08-15 |
| Clinical Trial to Assess the Immunogenicity and Safety of the Vero Cell-derived JE Vaccine in Korea JE vaccine - Japanese Encephalitis | Phase 3 | Completed | Boryung Pharmaceutical Co., Ltd | 205 | 2010-08-01 | 2014-01-30 |
| Immunogenicity and Safety of Inactivated Vero Cell Derived Japanese Encephalitis Vaccine in Thai Children JEVAC - Encephalitis, Japanese B | Phase 3 | Completed | Mahidol University | 152 | 2010-05-01 | 2014-11-18 |
| A Study of Japanese Encephalitis Chimeric Virus Vaccine Compared With SA14-14-2 Vaccine in Infants and Toddlers Japanese encephalitis chimeric virus vaccine (JE-CV), Japanese encephalitis live vaccine (SA14-14-2 vaccine) (CD.JEVAX®) - Encephalitis, Japanese Encephalitis | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 300 | 2010-03-01 | 2013-12-25 |
| Long-term Follow-up of Immunogenicity of a Single Dose of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Toddlers Blood sample, JE-CV administered in Study JEC02 - Encephalitis, Japanese Encephalitis | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 596 | 2009-08-07 | 2017-11-29 |
| Immunogenicity, Safety and Interchangeability of Two Tbe Vaccines Administered According to a Conventional Schedule in Children Tick-Borne Encephalitis (TBE) Vaccine (Inactivated) - Encephalitis, Tick-Borne | Phase 3 | Completed | Pfizer | 302 | 2009-02-06 | 2024-01-19 |
| Immunogenicity of a Commercial Batch of JEV IC51 up to 24 Months Post Filling IC51 - Japanese Encephalitis | Phase 3 | Completed | Valneva Austria GmbH | 304 | 2008-09-01 | 2016-05-04 |
Showing 20 of 39. Sign in to see all of them.
Encephalitis, Japanese (30) · Encephalitis, Tick-Borne (9) · Encephalitis (4) · Rabies (2) · Chickenpox (1) · Hepatitis A (1) · Measles (1) · Meningitis, Meningococcal (1) · Meningococcal Infections (1) · Mumps (1) · Rubella (1) · Typhoid Fever (1) · Yellow Fever (1)
Arbovirus Infections (39) · Brain Diseases (39) · Central Nervous System Diseases (39) · Central Nervous System Infections (39) · Central Nervous System Viral Diseases (39) · Encephalitis, Arbovirus (39) · Encephalitis, Viral (39) · Flaviviridae Infections (39) · Flavivirus Infections (39) · Infections (39) · Nervous System Diseases (39) · Neuroinflammatory Diseases (39) · RNA Virus Infections (39) · Vector Borne Diseases (39)
Japanese Encephalitis Vaccines (4) · Vaccines (4) · Blood Specimen Collection (2) · Hepatitis A Vaccines (2) · SA-14-14-2 vaccine (2) · Chickenpox Vaccine (1) · ChimeriVax (1) · Immunization, Secondary (1) · Measles Vaccine (1) · MenACWY-CRM vaccine (1) · Rabies Vaccines (1) · Saline Solution (1) · Vi polysaccharide vaccine, typhoid (1) · Yellow Fever Vaccine (1)
Valneva Austria GmbH (11) · Sanofi Pasteur, a Sanofi Company (8) · Pfizer (7) · PATH (2) · Sanofi (2) · Sormland County Council, Sweden (2) · Boryung Pharmaceutical Co., Ltd (1) · Helsinki University Central Hospital (1) · Jiangsu Province Centers for Disease Control and Prevention (1) · Mahidol University (1) · National Institute of Hygiene and Epidemiology, Vietnam (1) · Novartis (1) · Novartis Vaccines (1)
Austria (7) · Germany (7) · Philippines (6) · Poland (4) · Thailand (4) · Australia (3) · South Korea (3) · United States (3) · Czechia (2) · Finland (2) · Sweden (2) · Vietnam (2) · China (1) · Japan (1) · Switzerland (1)
Astrid Kaltenboeck, Ph.D. (3) · Jerzy Brzostek, MD (2) · Jerzy Dziduch, MD (2) · Jerzy Romaszko, MD (2) · Krzysztof Sladek, MD (2) · Marian Patrzalek, MD (2) · Salvacion Gatchalian, MD (2) · Susanne Eder (2) · Susanne Eder, Mag. (2) · Andrea Ayad, Dr. (1) · Anu Kantele, MD PhD (1)
PMID 20934459, PMID 18394765, PMID 21288804, PMID 22696017, PMID 22777096, PMID 24656175, PMID 24717964, PMID 24873986, PMID 25308927, PMID 25483480, PMID 25567119, PMID 26005163, PMID 26994987, PMID 29081368, PMID 29325161, PMID 32156630, PMID 35101266, PMID 38614954
2008 (1)